TP53 and neoplasm: Shah and colleagues58 examined the mutational spectrum in triple‐negative breast cancer (ER/progesterone receptor/HER‐negative), again finding that TP53 and PIK3CA mutations were clonally dominant, but also finding a wide variety of mutation spectra, including tumours with few driving mutations and tumours with extremely complex mutational spectra (the hypermutated phenotype).